AXOVANT GENE THERAPIES LTD - COM (AXGT)

CUSIP: G0750W203

Q4 2019 13F Holders as of 31 Dec 2019

Type / Class
Equity / COM
Total 13F shares
2,611,986
Share change
-946,994
Total reported value
$13,373,056
Put/Call ratio
38%
Price per share
$5.12
Number of holders
37
Value change
-$5,224,498
Number of buys
14
Number of sells
20

Quarterly Holders Quick Answers

What is CUSIP G0750W203?
CUSIP G0750W203 identifies AXGT - AXOVANT GENE THERAPIES LTD - COM in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Institutional Holders of AXOVANT GENE THERAPIES LTD - COM (AXGT) as of Q4 2019

As of 31 Dec 2019, AXOVANT GENE THERAPIES LTD - COM (AXGT) was held by 37 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 2,611,986 shares. The largest 10 holders included Hudson Bay Capital Management LP, SPHERA FUNDS MANAGEMENT LTD., RENAISSANCE TECHNOLOGIES LLC, Ikarian Capital, LLC, CITADEL ADVISORS LLC, ADAGE CAPITAL PARTNERS GP, L.L.C., PRIMECAP MANAGEMENT CO/CA/, Caption Management, LLC, Marshall Wace North America L.P., and GROUP ONE TRADING, L.P.. This page lists 37 institutional shareholders reporting positions in this security for the Q4 2019 filing period.
Investor Option Weight % Change % Value $ * Price Shares Share Change Activity Report Period
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.